Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956278 · ClinicalTrials.gov registry record · Phase 4
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
A Phase 4 study of Hyperuricemia and Chronic Gout, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT02956278 is a Phase 4 study of Hyperuricemia and Chronic Gout that has completed, run by University of California, San Francisco. The registered enrollment target is 27 participants, below the 162-participant average among 11 other Hyperuricemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02956278, a Phase 4 study of Hyperuricemia and Chronic Gout, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Allopurinol
Study Locations (1)
California
- Open Medicine Institute - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956278
The ClinicalTrials.gov registry entry for NCT02956278 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 11 other Hyperuricemia trials with a reported enrollment target (83% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hyperuricemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02956278 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02956278 about?
NCT02956278 is a clinical study titled "The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics". Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
What is the current status of trial NCT02956278?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2016-11. Estimated completion is 2018-03.
What conditions does trial NCT02956278 study?
This clinical trial studies the following conditions: Hyperuricemia, Chronic Gout.
What interventions are being tested in trial NCT02956278?
The interventions under investigation include: Placebo (OTHER), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT02956278?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02956278 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperuricemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
ACTIVE NOT RECRUITING · Phase 3
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.